News | February 08, 2024
MIRA Pharmaceuticals announces collaboration with Pharmaseed
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Submission to be reviewed under FDA real-time oncology review and Project Orbis
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Subscribe To Our Newsletter & Stay Updated
